Drugs that contain Baricitinib

1. Drug name - OLUMIANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

CN103788098A ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitor
May, 2016

(6 years ago)

CN102026999B ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitor
Mar, 2029

(6 years from now)

CN102026999A ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

IN201001863P3 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

IN270765B ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

EP2288610B1 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

EP2288610A1 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

EP2288610B8 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors Mar, 2029

(6 years from now)

Treatment: Treatment of rheumatoid arthritis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.